Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer

BACKGROUND: Despite improved outcomes with the introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor EGFR-activating mutations, unfortunately most patients eventually...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Feng, Liu, Xuewen, Bartholdy, Boris A., Cheng, Haiying, Halmos, Balazs
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798913/
https://www.ncbi.nlm.nih.gov/pubmed/35116995
http://dx.doi.org/10.21037/tcr.2019.09.61

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798913/
https://www.ncbi.nlm.nih.gov/pubmed/35116995
http://dx.doi.org/10.21037/tcr.2019.09.61

Ejemplares similares